The epithelial type 1 transmembrane mucin MUC1 is long-established as a marker for monitoring recurrence of breast cancer, and beyond its diagnostic marker qualities, it is a promising target for immunotherapeutic strategies to treat cancer by active specific immunization. The mucin is able to break tolerance and to induce humoral immune responses in healthy subjects and in cancer patients, but the response is generally weak. These natural responses to tumour-associated MUC1 glycoforms indicate that antibody reactivities are more directed to glycopeptide than to non-glycosylated peptide epitopes. To overcome the weak immunogenicity of heavily O-glycosylated MUC1, the question of whether O-linked glycans remain intact during processing in the MHC class II pathway was addressed. Attempts were made to define site-specific O-glycosylation and the structural requirements for efficient endosomal proteolysis by cathepsin L in dendritic cells. A fraction of glycopeptides survive the processing machinery, and have the capacity to bind to MHC class II and to activate sub-populations of glycopeptide-specific helper T-cell clones as a prerequisite for strong and long-lasting immune responses to MUC1-positive tumours. Moreover, studies on clusters of sequence-variant repeats, which are interspersed in the repeat domain of MUC1 at high frequency, have revealed that a limited set of concerted amino-acid replacements (Asp-Thr 0 -Arg 1 -Pro 10 to Glu-Ser 0 -Arg 1 -Ala 10 ) contributes considerably to increased peptide flexibility and to under-glycosylation of sequence-variant repeats which in concert modify immunological features of the mucin. Peptides and glycopeptides with the immunodominant DTR (Asp-ThrArg) or with the variant ESR (Glu-Ser-Arg) motif, and highly immunogenic peptides of the degenerate repeats that flank the repeat domain are currently evaluated as potential targets in multi-epitopic adjuvant-based vaccine strategies for their capacity to induce cytotoxic T-cell responses.
In the light of these well-established immunological principles, it is evident why carbohydrates cannot become immunogenic via the classical MHC pathways. However, many proteins belong to the family of glycoproteins, which may comprise more than half of all proteins considering N-and O-glycosylation. Glycosylation not only introduces novel potential epitopes into a protein, but also causes a series of restrictions owing to sterical hindrance by the bulky carbohydrate chains. First of all, O-linked glycans are known to protect peptide backbones of proteins from ready proteolytic digestion. It can be expected, accordingly, that glycoproteins are ineffectively processed. Secondly, even if the processing machinery forms glycopeptide fragments of appropriate sizes, their binding to MHC protein could be disturbed by the glycans [1] . Finally, we have to consider that similar restrictions apply to complex formation with the TCR [1] . It is not surprising, accordingly, that heavily O-glycosylated proteins, such as natural glycoforms of human MUC1 from tumour ascites, are poor immunogens [2] .
The question of whether O-linked glycans remain intact at all during processing, or whether they are partially or totally degraded, was addressed in a collaborative study with Dr Olivera Finn from the University of Pittsburgh. Human and mouse DCs (dendritic cells) were used as APCs, and the processing and presentation of a set of synthetic MUC1-based glycopeptides was measured by monitoring hybridoma helper T-cell activation [3] . The results of the study revealed that core-type glycans, such as GalNAc and Gal-GalNAc, and also larger (although artificial) structures, remain bound to the peptides on their way through the cellular processing machinery and that they bind quite effectively as glyco-peptides to the MHC class II protein. This became evident from lectin staining of surface-presented glycopeptides, and from the site-specific effects exerted by the glycans [3] . Only those processed glycopeptides were capable of activating hybridoma T-cells that carried O-linked chains in the GSTA (Gly-Ser-Thr-Ala) motif of the repeat peptide AHGVTSA PDTRPAPGSTAPP. Glycopeptides with glycosylation at VTSA (Val-Thr-Ser-Ala) or PDTR (Pro-Asp-Thr-Arg) motifs were inactive [3] . One plausible explanation for the finding can be seen in the hybridoma TCR that, in this case, bound to the non-glycosylated PDTR motif, and hence was blocked by O-glycosylation of the motif.
But why does O-glycosylation of the VTSA motif prevent T-cell activation? This question was addressed in a systematic study of in vitro and cellular glycopeptide processing [4] . Human and mouse DCs were pulsed with an array of MUC1 repeat glycopeptides of different lengths that carried GalNAc or Gal-GalNAc in various single or multiple positions. Proteolytic fragments in cellular extracts or in culture supernatants (protease-free) were enriched by solid-phase extraction and analysed by MS. This approach apparently decoupled processing from other steps in the T-cell activation process and revealed insight, on the biochemical level, into the site-specificity of endosomal proteolysis and into sitespecific effects exerted by the attached glycans on peptide cleavage. Peptides comprising five non-glycosylated 20-meric repeats of the MUC1 VNTR (variable number of tandem repeats) domain yielded a surprisingly restricted number of fragments ranging from 17-mers to 27-mers (SAP17, GVT20, SAP20, GVT23, and STA27) (Figure 1 ). SAP17, as the major product of cellular processing, was also formed in mouse DCs that had been pulsed with MUC1 glycopeptides. However, only those glycopeptides that carried GalNAc at PDTR or GSTA motifs were processed, whereas no SAP17 with O-glycosylation at VTSA was detectable [4] (Figure 2 ). This finding can be explained by assuming that glycans in positions adjacent to the proteolytic cleavage site [VT-SA (-indicates the site of cleavage)] sterically hinder access of the protease. The enzyme involved in endosomal processing of human and mouse DCs was identified as the cysteine-protease cathepsin L [4] . In vitro studies with this enzyme confirmed the assumption that O-glycans at either threonine or serine in VTSA make the major processing site of the repeat peptide resistant to proteolysis by cathepsin L [4] . The effect is exerted already at the monosaccharide level. The enzyme tolerates O-glycosylation at other sites, even if more complex glycans, such as NeuAc-Gal-GalNAc, are linked to the peptide (F.-G. Hanisch, unpublished work). The two other cathepsin L cleavage sites in the repeat peptide (AH-GV and PG-ST) are strongly affected by glycan elongation. Although these sites are effectively used in the non-glycosylated 100-mer, and moderately used in the GalNAc-modified 100-mer, addition of Gal to the core-GalNAc inhibits any in vitro proteolysis [4] . These findings from in vitro studies are in accordance with mouse immunization studies and the known immunological inertness of natural MUC1 glycoforms that carry complex glycans which, owing to the site preferences of the ubiquitously expressed polypeptide N-acetylgalactosamine transferases T1 and T2, are mostly linked to threonine/serine in the VTSA motif.
One point needs to be added: The patterns of peptide fragments generated in vitro by cathepsin L proteolysis are more complex than those from cellular processing ( Figure 1B) . They comprise peptides ranging from 7-mers to 33-mers (F.-G. Hanisch, unpublished work), while DC-processing products range from 17-mers to 27-mers [4] . This can be explained by assuming that peptides in complex with MHC class II are protected from further degradation. Accordingly, only those peptides would survive the processing-active endosomes that match the optimal size range and anchorresidue configuration for MHC class II binding ( Figures 1B  and 3 ). This leads to further assumptions concerning the origin of processed peptides in culture supernatants. Since these peptides fall into the size range for optimal MHC class II binding, it can be speculated that they leave the DC surface via multivesicular bodies and exocytosis of exosomes. DCderived exosomes have been shown, in a proteomic study, to contain MHC class I and class II proteins [5] .
In the mid 1990s, a series of studies had already revealed evidence that designed Tn-glycopeptides are able to bind to MHC class II E(k) and to elicit T-cell responses with carbohydrate and peptide specificity [6, 7] . In a later study, multicomponent glycopeptide libraries and single glycopeptides were used for immunization of mice, with the aim of inducing strong helper T-cell responses to the repeat peptide of MUC1 [8] . The glycopeptides were modelled by introducing amino acid replacements at MHC anchor positions in order to fulfil the binding requirements of the A(d) MHC class II in BALB/c mice optimally. While the native MUC1 glycopeptide was non-immunogenic, immunization with one of the designed glycopeptide libraries primed T-cells for a proliferative cross-response to the native MUC1 glycopeptide [8] .
Immunology of sequence-variant MUC1 repeats
Although the sequence data for a series of other human mucins had indicated considerable sequence variation in the tandem repeat domains, the 20-meric MUC1 repeat has long been regarded as being conserved. Structural evidence at the protein and DNA levels is now available, which reveals three positions in the repeat as highly polymorphic [9, 10] . These amino acid replacements are not randomly distributed over the entire domain, but instead show some degree of order that may be linked to the evolution of the mucin gene. Two replacements, Asp → Glu and Thr → Ser in the PDTR motif, always occur concertedly, while the third [Pro → Ala, Pro → Gln or Pro → Thr in the PAHG (Pro-Ala-His-Gly) motif] is often associated with the former [10] . Moreover, the concerted Asp-Thr → Glu-Ser replacement has been shown to occur mostly in clusters of sequence-variant repeats (diads, triads, tetrads) and displays a constant pattern in the peripheral domain topology [10, 11] . In summary, these findings indicate that the repeat domain of MUC1 may have evolved by successive duplications of superrepeats.
The sequence variations in the repeat domain have an impact on the conformation and on the O-glycosylation of the MUC1 peptide, which in turn should influence the immunological features of the mucin. First of all, the PDTR sequence has been identified in a number of studies as one of the immunodominant motifs in human and mouse. Most murine monoclonal antibodies, and a major fraction of natural human antibodies, are directed to this motif. As expected from the conservative nature of the concerted amino acid replacements (Asp-Thr → Glu-Ser), structural work on the peptide conformation of sequence-variant repeats by NMR have not revealed major differences. However, the 21-meric peptides and glycopeptides investigated in this study showed considerable differences in their conformational flexibilities, the PESR (Pro-Glu-Ser-Arg)-containing peptides being less rigid [12] . This property could be linked to an immunologically relevant feature, since more flexible peptides could overcome immune tolerance more easily and facilitate epitope adaptation. Moreover, sequence-variant repeats, in particular those with the configuration Glu-Ser 0 -Ala 10 , exhibit severe under-glycosylation in normal epithelial cells compared with invariant repeats with the Asp-Thr 0 -Pro 10 configuration [12] . Since sequence-variant repeats are mainly found in clusters, extended stretches of the mucin peptide should become accessible to the immune system. This aspect, together with the conformational differences, could underlie a recent finding that the natural IgG response in sera from healthy individuals, pregnant women or patients with benign tumours, was preferentially directed to variant repeats (this means, a higher frequency of serum samples showed preferential binding to the ESR motif). In cancer samples, frequency of preferential binding shifts towards the DTR motif, which again could be linked to tumour-associated O-glycosylation with shortened chains. Unpublished work by Dr V.M. Pisarev, University of Nebraska Medical Center, Omaha, NE, U.S.A. (personal communication) has revealed that nona-and deca-mers with either the ESR or the DTR motif can be strong inducers of cytotoxic T-cell responses. However, the immunogenic potentials of ESR/DTR peptide couples were dependent on the location of potential anchor residues involved in MHC class I binding. A recent study has shown that not only the repeat domain, but also other regions of MUC1, may participate in immune responses against tumours [13] . In this study, the combination of immuno-informatic molecular modelling and vaccine-adjuvant strategy was used to predict and describe a novel T-cell epitope, SAPDNRPAL, located within the degenerate tandem repeats of MUC1 that flank the repeat domain. This peptide is structurally similar to the regular repeat sequence SAPDTRPAP, but also to the Sendai virus peptide FAPGNYPAL, which are both known to induce cytotoxic T-lymphocytes. The degenerate nonapeptide, however, had a higher affinity for mouse H-D b , H-2K b and human HLA-A2 molecules than SAPDTRPAP. A further MHC class I epitope (HLA-A*0201), identical with a partial sequence of degenerate repeats, was also demonstrated to represent a dominant target for CD8
+ T-cells in gastro-intestinal cancer [14] . Such peptides could play a role in multiepitopic vaccine strategies.
Outlook
Can MUC1 glycopeptides induce cytotoxic T-cell responses via the MHC class I pathway?
Since the majority of MHC-class-I-binding peptides are derived from cytosolic proteins that have been targeted by ubiquitinylation and degraded by the proteasome, mucintype O-glycoproteins should not play a role at all, unless a certain extent of cross-priming by extracellular antigen is taken into consideration. A report on nucleocytosolic O-GlcNAcmodified glycopeptides, which were elutable from MHC class I, has demonstrated that O-glycosylation with monosaccharides could be tolerated by the proteasomes [15] . This finding was the starting point for currently ongoing work on the immunoproteasomal in vitro processing of MUC1 repeat glycopeptides. The current status of this work can be summarized by the statement that, despite a considerable reduction in cleavage efficiency, immunoproteasomes can hydrolyse O-glycopeptides with GalNAc or Gal-GalNAc in various positions to form 8-to 11-mers (T. Ninkovic and F.-G. Hanisch, unpublished work). However, the cleavage patterns, with respect to the preferred sites of proteolysis, are quite different between non-glycosylated and glycosylated MUC1 repeats. There are hints that some of the glycosylated nonamers formed are better binders in MHC class I stabilization assays than their non-glycosylated counterparts (T. Ninkovic and F.-G. Hanisch, unpublished work). A molecular modelling study with MUC1-based octa-and nonamers, has revealed that GalNAc in linkage to the central threonine residue in SAPDTRPA points into the C pocket and forms van der Waals and hydrogen bond interactions with certain alleles of the MHC class I protein [16] . Further studies are needed to confirm these initial findings and to develop, by these strategies, a glycopeptide-based MUC1 vaccine that can be expected to induce a strong and specific cytotoxic T-cell response in cancer patients.
